316-330 of 847
Developments in DMD Treatment: The First Nonsteroidal Drug Approval
Clinician's RoundtableDevelopments in DMD Treatment: The First Nonsteroidal Drug Approval
Recognizing and Addressing Medical Gaslighting in Healthcare
NeuroFrontiersRecognizing and Addressing Medical Gaslighting in Healthcare
Michele Longo, MD
A Potential Treatment for Parkinson's Disease Showing Safety and Tolerability
NeuroFrontiersA Potential Treatment for Parkinson's Disease Showing Safety and Tolerability
Research Identifies a Potential Link Between Sleep Apnea and Memory Loss
NeuroFrontiersResearch Identifies a Potential Link Between Sleep Apnea and Memory Loss
Breastfeeding with MS: Monoclonal Antibodies May Not Impact Child Development
NeuroFrontiersBreastfeeding with MS: Monoclonal Antibodies May Not Impact Child Development
Exploring the Clinical Treatments of Schizophrenia
NeuroFrontiersExploring the Clinical Treatments of Schizophrenia
Ashley Baker, MSN, PMHNP
Nabil Ali, MD
- advertisement
The Role of Occupational Therapy in Schizophrenia Management
NeuroFrontiersThe Role of Occupational Therapy in Schizophrenia Management
Ashley Baker, MSN, PMHNP
Lauren Walker, OT
Investigating the Prevalence of Comorbidities in MS Clinical Trials
NeuroFrontiersInvestigating the Prevalence of Comorbidities in MS Clinical Trials
Ashley Baker, MSN, PMHNP
Amber Salter, PhD
Disparities in DMT Access: Women with MS Are Less Likely to Receive Treatment
NeuroFrontiersDisparities in DMT Access: Women with MS Are Less Likely to Receive Treatment
Andrew Wilner, MD, FACP, FAAN
Victoria Leavitt, PhD
Assessing Disability in MS Patients with the SNRS and CombiWISE Tools
NeuroFrontiersAssessing Disability in MS Patients with the SNRS and CombiWISE Tools
Andrew Wilner, MD, FACP, FAAN
Dejan Jakimovski, MD, PhD
The Alarming Shortage of ADHD Medication and Its Implications on Patients
NeuroFrontiersThe Alarming Shortage of ADHD Medication and Its Implications on Patients
Understanding the Cellular Basis for Altered Cognition in Schizophrenia
NeuroFrontiersUnderstanding the Cellular Basis for Altered Cognition in Schizophrenia
Ashley Baker, MSN, PMHNP
Samuel Dienel, PhD
- advertisement
Practices for Preventing Polypharmacy in Multiple Sclerosis
NeuroFrontiersPractices for Preventing Polypharmacy in Multiple Sclerosis
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Ahmed Z. Obeidat, MD, PhD
Lauren Beranek, BS
From Assessment to Management: Tackling Catatonia in Schizophrenic Patients
NeuroFrontiersFrom Assessment to Management: Tackling Catatonia in Schizophrenic Patients
Ashley Baker, MSN, PMHNP
Stanley N. Caroff, MD
How Alzheimer's and Lewy Body Pathology Impact CAA Risk Factors
NeuroFrontiersHow Alzheimer's and Lewy Body Pathology Impact CAA Risk Factors
Charles Turck, PharmD, BCPS, BCCCP
Jagan Pillai, MD, PhD
